Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IMM02-KORA
- Development stage
- Unknown
- Lead developer
- Immunis
- Modality
- Small Molecules
- Administration
- Oral, Intraperitoneal
01
Overview
IMM02-KORA (also known as KORA) is a small molecule kappa opioid receptor (KOR) agonist being developed for the treatment of dyskinesia associated with Parkinson's disease, specifically levodopa-induced dyskinesia (LID). Originally developed by Toray Industries, the candidate was licensed to Immunis for development and commercialization in the United States, Canada, and Europe. The drug functions by selectively activating kappa opioid receptors in the brain, which are involved in modulating the dopaminergic pathways that become overactive during chronic levodopa therapy. Preclinical studies in rat models have shown that IMM02-KORA can significantly reduce dyskinesia scores. Immunis has submitted an Investigational New Drug (IND) application to the FDA to initiate Phase I clinical trials.
- Other names
- Kappa opioid receptor agonist
02
Targets
KOR (Kappa opioid receptor)
Beyond the preview
Go deeper on IMM02-KORA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IMM02-KORA.